Ipratropium Bromide Adult Dosing
For adults with asthma exacerbations, use ipratropium bromide 0.5 mg via nebulizer every 20 minutes for 3 doses (then as needed), or 8 puffs via MDI every 20 minutes for up to 3 hours. 1
Nebulized Therapy
The standard adult dose for nebulized ipratropium bromide is 0.5 mg (using 0.25 mg/mL solution) every 20 minutes for 3 doses, then as needed during acute exacerbations 1. This dosing is specifically for severe asthma or COPD exacerbations when added to short-acting beta-agonist (SABA) therapy.
For maintenance therapy in stable COPD, the FDA-approved dosing is 500 mcg (one unit-dose vial) administered three to four times daily, with doses 6 to 8 hours apart 2. The nebulized solution can be mixed with albuterol or metaproterenol if used within one hour 2.
Key Points for Nebulized Therapy:
- Should not be used as first-line therapy—always add to SABA therapy for severe exacerbations 1
- May be mixed in the same nebulizer with albuterol 1
- Benefit diminishes once patient is hospitalized—the addition of ipratropium has not shown further benefit after hospital admission 1
Metered-Dose Inhaler (MDI)
The adult dose for ipratropium MDI (18 mcg/puff) is 8 puffs every 20 minutes as needed for up to 3 hours during acute exacerbations 1.
For combination ipratropium/albuterol MDI (each puff contains 18 mcg ipratropium + 90 mcg albuterol): 8 puffs every 20 minutes as needed for up to 3 hours 1.
Important Caveats:
Timing matters: Ipratropium should only be used for the initial 3 hours of severe exacerbations 1. Studies have specifically examined ipratropium MDI for up to 3 hours, and continuing beyond hospitalization provides no additional benefit.
Not for monotherapy in acute settings: The guidelines explicitly state ipratropium should be added to SABA therapy, not used alone, particularly in severe exacerbations 1.
Dose-response considerations: Research shows that in stable COPD, 0.4-0.6 mg nebulized doses achieve optimal bronchodilation, significantly more than the standard 40 mcg MDI dose 3. However, for acute exacerbations, the guideline-recommended 0.5 mg nebulized dose every 20 minutes for 3 doses remains the standard 1.